FDA approval of several inhibitors of the VEGF pathway has enabled significant advances in
the therapy of cancer and neovascular age-related macular degeneration. However, similar
to other therapies, inherent/acquired resistance to anti-angiogenic drugs may occur in
patients, leading to disease progression. So far the lack of predictive biomarkers has
precluded identification of patients most likely to respond to such treatments. Recent suggest
that both tumor and non-tumor (stromal) cell types are involved in the reduced …